Cargando…
Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure
OBJECTIVES: We analysed the prevalence of M184V/I and/or K65R/E/N mutations archived in proviral DNA (pDNA) in youths with perinatal HIV, virological control and who previously carried these resistance mutations in historic plasma samples. METHODS: We included vertically HIV-infected youths/young ad...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212770/ https://www.ncbi.nlm.nih.gov/pubmed/33734374 http://dx.doi.org/10.1093/jac/dkab080 |
_version_ | 1783709702986661888 |
---|---|
author | Jiménez de Ory, Santiago Beltrán-Pavez, Carolina Gutiérrez-López, Miguel Santos, María Del Mar Prieto, Luis Sainz, Talía Guillen, Sara Aguilera-Alonso, David Díez, Cristina Bernardino, Jose Ignacio Mellado, María José Ramos, José Tomás Holguín, África Navarro, Marisa |
author_facet | Jiménez de Ory, Santiago Beltrán-Pavez, Carolina Gutiérrez-López, Miguel Santos, María Del Mar Prieto, Luis Sainz, Talía Guillen, Sara Aguilera-Alonso, David Díez, Cristina Bernardino, Jose Ignacio Mellado, María José Ramos, José Tomás Holguín, África Navarro, Marisa |
author_sort | Jiménez de Ory, Santiago |
collection | PubMed |
description | OBJECTIVES: We analysed the prevalence of M184V/I and/or K65R/E/N mutations archived in proviral DNA (pDNA) in youths with perinatal HIV, virological control and who previously carried these resistance mutations in historic plasma samples. METHODS: We included vertically HIV-infected youths/young adults aged ≥10 years in the Madrid Cohort of HIV-1 Infected Children and Adolescents, exposed to lamivudine and/or emtricitabine, with M184V/I and/or K65R/E/N in historic plasma samples, on antiretroviral therapy (ART), virologically suppressed (HIV-1 RNA <50 copies/mL), and with available PBMCs in the Spanish HIV BioBank. Genomic DNA was extracted from PBMCs and HIV-1 RT gene was amplified and sequenced for resistance testing by Stanford HIV Resistance tool. RESULTS: Among the 225 patients under follow-up in the study cohort, 13 (5.8%) met selection criteria, and RT sequences were recovered in 12 (92.3%) of them. All but one were Spaniards, carrying subtype B, with a median age at PBMCs sampling of 21.3 years (IQR: 15.6–23.1) with 4 years (IQR 2.1–6.5) of suppressed viral load (VL). Nine (75%) youths did not present M184V/I in pDNA after at least 1 year of viral suppression. In December 2019, the remaining three subjects carrying M184V/I in pDNA maintained suppressed viraemia, and two still used emtricitabine in ART. CONCLUSIONS: The prevalence of resistance mutations to lamivudine and emtricitabine in pDNA in a cohort of youths perinatally infected with HIV who remain with undetectable VL, previously lamivudine and/or emtricitabine experienced, was infrequent. Our results indicate that ART including lamivudine or emtricitabine may also be safe and successful in youths with perinatal HIV with previous experience of and resistances to these drugs detected in plasma. |
format | Online Article Text |
id | pubmed-8212770 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-82127702021-06-21 Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure Jiménez de Ory, Santiago Beltrán-Pavez, Carolina Gutiérrez-López, Miguel Santos, María Del Mar Prieto, Luis Sainz, Talía Guillen, Sara Aguilera-Alonso, David Díez, Cristina Bernardino, Jose Ignacio Mellado, María José Ramos, José Tomás Holguín, África Navarro, Marisa J Antimicrob Chemother Original Research OBJECTIVES: We analysed the prevalence of M184V/I and/or K65R/E/N mutations archived in proviral DNA (pDNA) in youths with perinatal HIV, virological control and who previously carried these resistance mutations in historic plasma samples. METHODS: We included vertically HIV-infected youths/young adults aged ≥10 years in the Madrid Cohort of HIV-1 Infected Children and Adolescents, exposed to lamivudine and/or emtricitabine, with M184V/I and/or K65R/E/N in historic plasma samples, on antiretroviral therapy (ART), virologically suppressed (HIV-1 RNA <50 copies/mL), and with available PBMCs in the Spanish HIV BioBank. Genomic DNA was extracted from PBMCs and HIV-1 RT gene was amplified and sequenced for resistance testing by Stanford HIV Resistance tool. RESULTS: Among the 225 patients under follow-up in the study cohort, 13 (5.8%) met selection criteria, and RT sequences were recovered in 12 (92.3%) of them. All but one were Spaniards, carrying subtype B, with a median age at PBMCs sampling of 21.3 years (IQR: 15.6–23.1) with 4 years (IQR 2.1–6.5) of suppressed viral load (VL). Nine (75%) youths did not present M184V/I in pDNA after at least 1 year of viral suppression. In December 2019, the remaining three subjects carrying M184V/I in pDNA maintained suppressed viraemia, and two still used emtricitabine in ART. CONCLUSIONS: The prevalence of resistance mutations to lamivudine and emtricitabine in pDNA in a cohort of youths perinatally infected with HIV who remain with undetectable VL, previously lamivudine and/or emtricitabine experienced, was infrequent. Our results indicate that ART including lamivudine or emtricitabine may also be safe and successful in youths with perinatal HIV with previous experience of and resistances to these drugs detected in plasma. Oxford University Press 2021-03-18 /pmc/articles/PMC8212770/ /pubmed/33734374 http://dx.doi.org/10.1093/jac/dkab080 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Research Jiménez de Ory, Santiago Beltrán-Pavez, Carolina Gutiérrez-López, Miguel Santos, María Del Mar Prieto, Luis Sainz, Talía Guillen, Sara Aguilera-Alonso, David Díez, Cristina Bernardino, Jose Ignacio Mellado, María José Ramos, José Tomás Holguín, África Navarro, Marisa Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure |
title | Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure |
title_full | Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure |
title_fullStr | Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure |
title_full_unstemmed | Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure |
title_short | Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure |
title_sort | prevalence of m184v and k65r in proviral dna from pbmcs in hiv-infected youths with lamivudine/emtricitabine exposure |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212770/ https://www.ncbi.nlm.nih.gov/pubmed/33734374 http://dx.doi.org/10.1093/jac/dkab080 |
work_keys_str_mv | AT jimenezdeorysantiago prevalenceofm184vandk65rinproviraldnafrompbmcsinhivinfectedyouthswithlamivudineemtricitabineexposure AT beltranpavezcarolina prevalenceofm184vandk65rinproviraldnafrompbmcsinhivinfectedyouthswithlamivudineemtricitabineexposure AT gutierrezlopezmiguel prevalenceofm184vandk65rinproviraldnafrompbmcsinhivinfectedyouthswithlamivudineemtricitabineexposure AT santosmariadelmar prevalenceofm184vandk65rinproviraldnafrompbmcsinhivinfectedyouthswithlamivudineemtricitabineexposure AT prietoluis prevalenceofm184vandk65rinproviraldnafrompbmcsinhivinfectedyouthswithlamivudineemtricitabineexposure AT sainztalia prevalenceofm184vandk65rinproviraldnafrompbmcsinhivinfectedyouthswithlamivudineemtricitabineexposure AT guillensara prevalenceofm184vandk65rinproviraldnafrompbmcsinhivinfectedyouthswithlamivudineemtricitabineexposure AT aguileraalonsodavid prevalenceofm184vandk65rinproviraldnafrompbmcsinhivinfectedyouthswithlamivudineemtricitabineexposure AT diezcristina prevalenceofm184vandk65rinproviraldnafrompbmcsinhivinfectedyouthswithlamivudineemtricitabineexposure AT bernardinojoseignacio prevalenceofm184vandk65rinproviraldnafrompbmcsinhivinfectedyouthswithlamivudineemtricitabineexposure AT melladomariajose prevalenceofm184vandk65rinproviraldnafrompbmcsinhivinfectedyouthswithlamivudineemtricitabineexposure AT ramosjosetomas prevalenceofm184vandk65rinproviraldnafrompbmcsinhivinfectedyouthswithlamivudineemtricitabineexposure AT holguinafrica prevalenceofm184vandk65rinproviraldnafrompbmcsinhivinfectedyouthswithlamivudineemtricitabineexposure AT navarromarisa prevalenceofm184vandk65rinproviraldnafrompbmcsinhivinfectedyouthswithlamivudineemtricitabineexposure AT prevalenceofm184vandk65rinproviraldnafrompbmcsinhivinfectedyouthswithlamivudineemtricitabineexposure |